Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Prevention
1.2.3 Physiotherapy
1.2.4 Immunity Therapy
1.3 Market by Application
1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2017-2028)
2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Region
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Dynamics
2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Trends
2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
6.2.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
6.3.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
6.4.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
7.2.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
7.3.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
7.4.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
9.2.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
9.3.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
9.4.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achaogen
11.1.1 Achaogen Company Details
11.1.2 Achaogen Business Overview
11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.1.5 Achaogen Recent Developments
11.2 Adenium Biotech
11.2.1 Adenium Biotech Company Details
11.2.2 Adenium Biotech Business Overview
11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.2.5 Adenium Biotech Recent Developments
11.3 Aridis Pharmaceuticals
11.3.1 Aridis Pharmaceuticals Company Details
11.3.2 Aridis Pharmaceuticals Business Overview
11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.3.5 Aridis Pharmaceuticals Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.4.5 AstraZeneca Recent Developments
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.5.5 Bayer Recent Developments
11.6 Cardeas Pharma
11.6.1 Cardeas Pharma Company Details
11.6.2 Cardeas Pharma Business Overview
11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.6.5 Cardeas Pharma Recent Developments
11.7 Destiny Pharma
11.7.1 Destiny Pharma Company Details
11.7.2 Destiny Pharma Business Overview
11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.7.5 Destiny Pharma Recent Developments
11.8 Dong-A Socio Holdings
11.8.1 Dong-A Socio Holdings Company Details
11.8.2 Dong-A Socio Holdings Business Overview
11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.8.5 Dong-A Socio Holdings Recent Developments
11.9 Lakewood-Amedex
11.9.1 Lakewood-Amedex Company Details
11.9.2 Lakewood-Amedex Business Overview
11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.9.5 Lakewood-Amedex Recent Developments
11.10 MedImmune
11.10.1 MedImmune Company Details
11.10.2 MedImmune Business Overview
11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.10.5 MedImmune Recent Developments
11.11 Meiji Seika Pharma
11.11.1 Meiji Seika Pharma Company Details
11.11.2 Meiji Seika Pharma Business Overview
11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.11.5 Meiji Seika Pharma Recent Developments
11.12 Merck & Co
11.12.1 Merck & Co Company Details
11.12.2 Merck & Co Business Overview
11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.12.5 Merck & Co Recent Developments
11.13 Motif Bio
11.13.1 Motif Bio Company Details
11.13.2 Motif Bio Business Overview
11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.13.5 Motif Bio Recent Developments
11.14 Nabriva Therapeutics
11.14.1 Nabriva Therapeutics Company Details
11.14.2 Nabriva Therapeutics Business Overview
11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.14.5 Nabriva Therapeutics Recent Developments
11.15 Polyphor
11.15.1 Polyphor Company Details
11.15.2 Polyphor Business Overview
11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.15.5 Polyphor Recent Developments
11.16 Shionogi & Co
11.16.1 Shionogi & Co Company Details
11.16.2 Shionogi & Co Business Overview
11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.16.5 Shionogi & Co Recent Developments
11.17 Tetraphase Pharmaceuticals
11.17.1 Tetraphase Pharmaceuticals Company Details
11.17.2 Tetraphase Pharmaceuticals Business Overview
11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.17.5 Tetraphase Pharmaceuticals Recent Developments
11.18 The Medicines Company
11.18.1 The Medicines Company Company Details
11.18.2 The Medicines Company Business Overview
11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.18.5 The Medicines Company Recent Developments
11.19 Theravance Biopharma
11.19.1 Theravance Biopharma Company Details
11.19.2 Theravance Biopharma Business Overview
11.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.19.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.19.5 Theravance Biopharma Recent Developments
11.20 Wockhardt
11.20.1 Wockhardt Company Details
11.20.2 Wockhardt Business Overview
11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.20.5 Wockhardt Recent Developments
11.21 Zavante Therapeutics
11.21.1 Zavante Therapeutics Company Details
11.21.2 Zavante Therapeutics Business Overview
11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.21.5 Zavante Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer